Here are the Lions Health winners in the health and wellness category.
It's still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
A combination of traditional and modern comms tactics help molecular diagnostic testing company Interpace craft messages that resonate with all key audiences.
New study finds early-stage breast cancer may not need chemo; Merck's Keytruda succeeds in more studies; Athenahealth CEO faces allegations of inappropriate behavior
MM&M/Publicis Health's first Diversity Survey reveals some notable shifts to making the healthcare industry more inclusive, yet many agencies didn't feel like opening up about their diversity numbers.
Sam Cannizzaro, executive creative director at GSW, a Syneos Health company,discusses the agency's response to the rapid pace of change in healthcare marketing.
As deepening healthcare forays by tech and e-commerce giants ratchet up the pressure on pharma to become more consumer friendly, drugmakers are still defining their new role.
MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.
Alisa Lask is VP and GM, U.S. aesthetic business unit of Galderma, Nestlé Skin Health.
Johanna Skilling is head of planning of Ogilvy CommonHealth Worldwide.
Neera Chaudhary is global president of healthcare of Golin.
Elena Cant is VP, global head of vaccine commercial, Takeda Vaccine Business Unit of Takeda.
Meghan Rivera is VP, digital customer engagement of Amag Pharmaceuticals.
Becky Chidester is CEO of Wunderman Health.
Wendy Blackburn is EVP, marketing and communications of Intouch Solutions.
Kathy Delaney is chief creative officer of Publicis Health.
Deborah Profit is VP, Otsuka Information Technology at Ostuka.
Wendy Lund is CEO of GCI Health.
Vanessa Thirion-Cullity is executive director, U.S. NET of Novartis Oncology.
MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.
Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.
Whether jurors will award a pharma Grand Prix, and whether US pharma will show up, are two open questions in the run-up to Lions Health.
Here's a recap of the Novartis-Michael Cohen crisis, which unfolded this week, including how the drugmaker has responded to scrutiny over its $1.2 million contract with Cohen's firm.
At the Asembia Specialty Pharma summit, speakers described a healthcare ecosystem in which specialty products will represent nearly half of all drug spending.
Paul LeVine, VP, Analytic Services for TrialCard, describes proven strategies that prevent patient adherence fall off, driven by evidenced-based design and patient engagement programs.
The healthcare sector has suffered a dip in public trust in major markets including France, India and the US, but Britons remain among the more trusting globally, according to the Edelman Health Trust Barometer.
Gary Scheiner, EVP and chief creative officer at GHG, discusses the inherent tension in day-to-day marketing for healthcare brands.
Both leaders were honored at Healthcare Businesswomen's Association 2018 Woman of the Year event in New York.
Remedy Health Media's Mike Collins discusses ways pharma and healthcare companies have shifted their strategies in the years after the success of blockbuster drugs.
Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.